UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: the synthesis and biological activities of RPR127963 an orally bioavailable inhibitor

Bioorganic & medicinal chemistry letters, 2003-09, Vol.13 (18), p.3097-3100

2003

Volltextzugriff (PDF)

Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma

American journal of respiratory and critical care medicine, 2007-03, Vol.175 (5), p.450-457

2007

Volltextzugriff (PDF)

Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A

Circulation (New York, N.Y.), 1999-06, Vol.99 (25), p.3292-3299

1999

Volltextzugriff (PDF)

Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR Exploration and Effective Bioisosteric Replacement of a phenyl substituent

Bioorganic & medicinal chemistry letters, 2003-09, Vol.13 (18), p.3091-3095

2003

Volltextzugriff (PDF)

Abstract CT036: Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT036-CT036

2018

Volltextzugriff (PDF)

RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase

The Journal of pharmacology and experimental therapeutics, 1997-05, Vol.281 (2), p.746

1997

Volltextzugriff (PDF)

Abstract CT009: Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT009-CT009

2017

Volltextzugriff (PDF)

A novel endothelial-derived lipase that modulates HDL metabolism

Nature genetics, 1999-04, Vol.21 (4), p.424-428

1999

Volltextzugriff (PDF)

Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma

Annals of allergy, asthma, & immunology, 2005-04, Vol.94 (4), p.465-472

2005

Volltextzugriff (PDF)

Loss of motoneuron microRNA-218 results in systemic neuromuscular failure

Amin, Neal Dilip

2016

Volltextzugriff (PDF)

Effect of an NK 1 /NK 2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma

American journal of respiratory and critical care medicine, 2007-03, Vol.175 (5), p.450-457

2007

Volltextzugriff (PDF)

RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent

Pharmacology, 1993, Vol.46 (1), p.13-22

1993

Volltextzugriff (PDF)

Effect of ciclesonide and fluticasone on hypothalamicpituitary-adrenal axis function in adults with mild-to-moderate persistent asthma

Annals of allergy, asthma, & immunology, 2005-04, Vol.94 (4), p.465-472

2005

Volltextzugriff (PDF)

Stent-induced Restenosis in the Swine Coronary Artery Is Inhibited by a Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, TKI963

Journal of cardiovascular pharmacology, 2003-06, Vol.41 (6), p.817-829

2003

Volltextzugriff (PDF)

Synthesis and antilipolytic activities of quinolyl carbanilates and related analogs

Journal of medicinal chemistry, 1987-01, Vol.30 (1), p.62-67

1987

Volltextzugriff (PDF)

Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: The synthesis and biological activities of RPR127963 an orally bioavailable inhibitor: Recent advances in the design of kinase inhibitors as novel therapeutic agents

Bioorganic & medicinal chemistry letters, 2003, Vol.13 (18), p.3097-3100

2003

Volltextzugriff (PDF)

Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR exploration and effective bioisosteric replacement of a phenyl substituent: Recent advances in the design of kinase inhibitors as novel therapeutic agents

Bioorganic & medicinal chemistry letters, 2003, Vol.13 (18), p.3091-3095

2003

Volltextzugriff (PDF)

Stent-induced restenosis in the swine coronary artery is inhibited by a platelet-derived growth factor receptor tyrosine kinase inhibitor, TK1963

Journal of cardiovascular pharmacology, 2003-06, Vol.41 (6), p.817-829

2003

Volltextzugriff (PDF)

MECHANISM FOR RELEASE OF ARACHIDONIC ACID DURING GUINEA PIG PLATELET AGGREGATION: A ROLE FOR THE DIACYLGLYCEROL LIPASE INHIBITOR RHC 80267 (COLLAGEN, THROMBIN, PAF)

AMIN, DILIP

1986

Volltextzugriff (PDF)

RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase

Naunyn-Schmiedeberg's archives of pharmacology, 1996-01, Vol.353 (2), p.233-240

1996

Volltextzugriff (PDF)

Enzyme inhibition during the conversion of squalene to cholesterol

Steroids, 1995-07, Vol.60 (7), p.475-483

1995

Volltextzugriff (PDF)

Inter-religious Marriage

Hinduism today, 2008-07, Vol.30 (3), p.9

Amin, Dilip

2008

Volltextzugriff (PDF)

More than words

Police review (London), 2005-07, Vol.8, p.22-23

Amin, Dilip

2005

Volltextzugriff (PDF)

Lovastatin is hypertriglyceridemic in Syrian Golden hamsters

Biochemical and biophysical research communications, 1988-12, Vol.157 (2), p.530-534

1988

Volltextzugriff (PDF)

1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase

Arzneimittel-Forschung, 1996-08, Vol.46 (8), p.759

1996

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(64)

Publikationsform

Sprache

Englisch
(75)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: the synthesis and biological activities of RPR127963 an orally bioavailable inhibitor

Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma

Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A

Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR Exploration and Effective Bioisosteric Replacement of a phenyl substituent

Abstract CT036: Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study

RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase

Abstract CT009: Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study

A novel endothelial-derived lipase that modulates HDL metabolism

Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma

Loss of motoneuron microRNA-218 results in systemic neuromuscular failure

Effect of an NK 1 /NK 2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma

RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent

Effect of ciclesonide and fluticasone on hypothalamicpituitary-adrenal axis function in adults with mild-to-moderate persistent asthma

Stent-induced Restenosis in the Swine Coronary Artery Is Inhibited by a Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, TKI963

Synthesis and antilipolytic activities of quinolyl carbanilates and related analogs

Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: The synthesis and biological activities of RPR127963 an orally bioavailable inhibitor: Recent advances in the design of kinase inhibitors as novel therapeutic agents

Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR exploration and effective bioisosteric replacement of a phenyl substituent: Recent advances in the design of kinase inhibitors as novel therapeutic agents

Stent-induced restenosis in the swine coronary artery is inhibited by a platelet-derived growth factor receptor tyrosine kinase inhibitor, TK1963

MECHANISM FOR RELEASE OF ARACHIDONIC ACID DURING GUINEA PIG PLATELET AGGREGATION: A ROLE FOR THE DIACYLGLYCEROL LIPASE INHIBITOR RHC 80267 (COLLAGEN, THROMBIN, PAF)

RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase

Enzyme inhibition during the conversion of squalene to cholesterol

Inter-religious Marriage

More than words

Lovastatin is hypertriglyceridemic in Syrian Golden hamsters

1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase

Suchergebnisse filtern